Should I buy or sell Beam Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares. View BEAM analyst ratings or view top-rated stocks .

What is Beam Therapeutics' stock price target for 2024?

11 brokerages have issued twelve-month target prices for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $105.00. On average, they expect the company's stock price to reach $48.80 in the next year. This suggests a possible upside of 67.2% from the stock's current price. View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts .

How have BEAM shares performed in 2023?

Beam Therapeutics' stock was trading at $39.11 at the start of the year. Since then, BEAM stock has decreased by 25.4% and is now trading at $29.19. View the best growth stocks for 2023 here .

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our BEAM earnings forecast .

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) issued its earnings results on Wednesday, November, 8th. The company reported ($1.22) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.11. The firm earned $17.20 million during the quarter, compared to analysts' expectations of $17.09 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 40.66% and a negative net margin of 384.62%. Beam Therapeutics's quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.56) EPS.

What ETFs hold Beam Therapeutics' stock?

ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , Global X Genomics & Biotechnology ETF (GNOM) , iShares Genomics Immunology and Healthcare ETF (IDNA) , ARK Genomic Revolution ETF (ARKG) , ARK Innovation ETF (ARKK) , Horizon Kinetics Medical ETF (MEDX) , Jacob Forward ETF (JFWD) and WisdomTree BioRevolution Fund (WDNA) .

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Editas Medicine (EDIT) , Cisco Systems (CSCO) , Block (SQ) , Skyworks Solutions (SWKS) , Akoustis Technologies (AKTS) , Invitae (NVTA) , QUALCOMM (QCOM) and Alector (ALEC) .

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.09%), FMR LLC (7.97%), Sumitomo Mitsui Trust Holdings Inc. (2.07%), Redmile Group LLC (1.80%), Baillie Gifford & Co. (1.07%) and JPMorgan Chase & Co. (0.81%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella , Graham K Cooper , John M Evans , John M Evans and Terry-Ann Burrell . View institutional ownership trends .

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Beam Therapeutics have any subsidiaries?

The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc.. Read More

Beam Therapeutics Stock Price, News & Analysis (NASDAQ:BEAM)

$29.40

+1.15 (+4.07%)

(As of 02:34 PM ET)

Compare

Today's Range: $28.27
▼
$29.86
50-Day Range: $17.69
▼
$30.76
52-Week Range: $16.95
▼
$51.60

Volume: 471,226 shs
Average Volume: 986,953 shs
Market Capitalization: $2.40 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $48.80

Beam Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.45 Rating Score
Upside/Downside: 67.2% Upside
$48.80 Price Target
Short Interest: Bearish
16.97% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.76
Based on 2 Articles This Week
Insider Trading: Selling Shares
$73,343 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.85) to ($4.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

474th out of 949 stocks

Biological Products, Except Diagnostic Industry

71st out of 146 stocks

4.2

Analyst's Opinion

Consensus Rating
Beam Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 5 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.80, Beam Therapeutics has a forecasted upside of 67.2% from its current price of $29.19.
Amount of Analyst Coverage
Beam Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
16.97% of the outstanding shares of Beam Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Beam Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Beam Therapeutics has recently decreased by 4.29%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Beam Therapeutics does not currently pay a dividend.
Dividend Growth
Beam Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BEAM.

2.6

News and Social Media Coverage

News Sentiment
Beam Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Beam Therapeutics this week, compared to 5 articles on an average week.
Search Interest
Only 10 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
4 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,343.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Beam Therapeutics is held by insiders.
Percentage Held by Institutions
80.64% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Beam Therapeutics are expected to grow in the coming year, from ($4.85) to ($4.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Beam Therapeutics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Beam Therapeutics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Beam Therapeutics has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Beam Therapeutics Stock (NASDAQ:BEAM)

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BEAM Stock News Headlines

December 4, 2023 | markets.businessinsider.com

Buy Rating Affirmed on Sana Biotechnology Amid Promising ARDENT Trial Results for SC291 Therapy

November 30, 2023 | seekingalpha.com

CRISPR Gene Editing: Beam Therapeutics

December 6, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 23, 2023 | finance.yahoo.com

Beam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 Shares

November 20, 2023 | msn.com

The 3 Best Gene Editing Stocks on the Frontier of Medicine

November 20, 2023 | markets.businessinsider.com

Plus Therapeutics Announces Positive Results From ReSPECT-GBM Phase 2 Study

November 18, 2023 | finance.yahoo.com

Is Beam Therapeutics Stock a Buy Now?

November 17, 2023 | finance.yahoo.com

What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

November 16, 2023 | msn.com

Verve Therapeutics: Why Great Results Aren't Enough

November 13, 2023 | msn.com

Verve Therapeutics’ stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment

November 10, 2023 | markets.businessinsider.com

Hold Rating on Beam Therapeutics: Evaluating Future Prospects, Financial Stability, and Recent Strategic Moves

November 10, 2023 | finance.yahoo.com

Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect?

November 9, 2023 | finance.yahoo.com

Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates

November 8, 2023 | msn.com

Beam Therapeutics GAAP EPS of -$1.22 beats by $0.03, revenue of $17.19M misses by $6.7M

November 7, 2023 | marketwatch.com

Verve Therapeutics Shares Jump 29% on Higher 3Q Revenue

November 6, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Castle Biosciences (CSTL) and Kura Oncology (KURA)

November 6, 2023 | markets.businessinsider.com

Positive Market Trends and Innovative Gene Editing Technology Drive Buy Rating for Beam Therapeutics

November 2, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Beam Therapeutics (BEAM) and Argenx Se (ARGX)

November 2, 2023 | finance.yahoo.com

Lilly buys out Beam in heart drug alliance with Verve

October 31, 2023 | msn.com

Eli Lilly Purchases Rights for Gene-Editing Treatments from Beam Therapeutics

October 31, 2023 | bizjournals.com

Beam sells opt-in rights to Eli Lilly for up to $600M

October 31, 2023 | finance.yahoo.com

After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?

October 31, 2023 | finance.yahoo.com

Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know

October 31, 2023 | msn.com

Lilly to Pay Beam Up to $600 Million for DNA-Editing Therapies

October 31, 2023 | finance.yahoo.com

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 30, 2023 | msn.com

With 1 Roadblock Down, Is Verve Therapeutics a Buy Now?

See More Headlines

Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BEAM
CUSIP: N/A
CIK: 1745999
Web: www.beamtx.com
Phone: 857-327-8775
Fax: N/A
Employees: 439
Year Founded: 2017

Price Target and Rating

Average Stock Price Target: $48.80
High Stock Price Target: $105.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +72.7%
Consensus Rating: Hold
Rating Score (0-4): 2.45
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-289,090,000.00
Net Margins: -384.62%
Pretax Margin: -383.39%
Return on Equity: -40.66%
Return on Assets: -23.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.72
Quick Ratio: 4.72

Sales & Book Value

Annual Sales: $60.92 million
Price / Sales: 37.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.41 per share
Price / Book: 2.71

Miscellaneous

Outstanding Shares: 81,500,000
Free Float: 77,918,000
Market Cap: $2.30 billion
Optionable: Not Optionable
Beta: 1.69

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. John M. Evans M.B.A. (Age 45)
CEO & Director
Comp: $1.11M
Dr. Giuseppe Ciaramella Ph.D. (Age 54)
President
Comp: $933.2k
Ms. Terry-Ann Burrell M.B.A. (Age 46)
CFO & Treasurer
Comp: $711.15k
Dr. Feng Zhang Ph.D.
Co-Founder
Dr. David R. Liu Ph.D.
Co-Founder
Dr. J. Keith Joung M.D.
Ph.D., Co-Founder
Dr. Nicole Gaudelli Ph.D.
Co-Founder
Dr. Alexis Komor Ph.D.
Co-Founder
Dr. Manmohan Singh Ph.D.
Chief Technology Officer
Dr. Gopi Shanker Ph.D.
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BEAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
View BEAM analyst ratings or view top-rated stocks.
What is Beam Therapeutics' stock price target for 2024?: 11 brokerages have issued twelve-month target prices for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $105.00. On average, they expect the company's stock price to reach $48.80 in the next year. This suggests a possible upside of 67.2% from the stock's current price.
View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts.
How have BEAM shares performed in 2023?: Beam Therapeutics' stock was trading at $39.11 at the start of the year. Since then, BEAM stock has decreased by 25.4% and is now trading at $29.19.
View the best growth stocks for 2023 here.
When is Beam Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our BEAM earnings forecast.
How were Beam Therapeutics' earnings last quarter?: Beam Therapeutics Inc. (NASDAQ:BEAM) issued its earnings results on Wednesday, November, 8th. The company reported ($1.22) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.11. The firm earned $17.20 million during the quarter, compared to analysts' expectations of $17.09 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 40.66% and a negative net margin of 384.62%. Beam Therapeutics's quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.56) EPS.
What ETFs hold Beam Therapeutics' stock?: ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and WisdomTree BioRevolution Fund (WDNA).

What other stocks do shareholders of Beam Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).
When did Beam Therapeutics IPO?: (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Beam Therapeutics' major shareholders?: Beam Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.09%), FMR LLC (7.97%), Sumitomo Mitsui Trust Holdings Inc. (2.07%), Redmile Group LLC (1.80%), Baillie Gifford & Co. (1.07%) and JPMorgan Chase & Co. (0.81%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends.
How do I buy shares of Beam Therapeutics?: Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Beam Therapeutics have any subsidiaries?: The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More

This page (NASDAQ:BEAM) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Beam Therapeutics Stock Price, News & Analysis (NASDAQ:BEAM)

Beam Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Beam Therapeutics Stock (NASDAQ:BEAM)

BEAM Stock Price History

BEAM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BEAM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™